(LYB) LyondellBasell Industries - NYSE
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 19.390m USD | Total Return: 2.8% in 12m
Avg Turnover: 332M
Qual. Beats: 0
Rev. Trend: -99.3%
Qual. Beats: 0
Warnings
High Debt/EBITDA (9.9) with thin interest coverage (-0.2)
Interest Coverage Ratio -0.2 is critical
Below Avwap Earnings
Tailwinds
No distinct edge detected
LyondellBasell Industries N.V. (NYSE: LYB) is a Netherlands-headquartered chemical company incorporated in 2009 and listed since 2010. It operates globally across five reporting segments: Olefins and Polyolefins–Americas; Olefins and Polyolefins–Europe, Asia, International; Intermediates and Derivatives; Advanced Polymer Solutions; and Technology. Its product range spans basic petrochemicals (ethylene, propylene, butadiene, aromatics), polyolefins (polyethylene and polypropylene), propylene oxide and derivatives, oxyfuels, and intermediate chemicals such as styrene monomer and acetyls, along with compounded engineered plastics, masterbatches, and specialty composites.
The company serves end markets including food packaging, home furnishings, automotive components, and paints and coatings. In addition to manufacturing, LyondellBasell licenses polyolefin process technologies and produces polyolefin catalysts, giving it a recurring licensing and specialty revenue stream alongside its commodity chemicals output. Classified under the GICS Materials sector and Commodity Chemicals sub-industry, the business is a large-cap, globally diversified producer whose margins are closely tied to petrochemical feedstock prices and the cyclicality of the broader chemicals industry.
- Polyolefin oversupply from Asian capacity pressures global margins
- European energy costs squeeze Olefins and Polyolefins segment margins
- Automotive demand softness weighs on Advanced Polymer Solutions growth
| Net Income: -793.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.90 > 1.0 |
| NWC/Revenue: 13.04% < 20% (prev 14.98%; Δ -1.94% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.57b > Net Income -793.0m |
| Net Debt (12.9b) to EBITDA (1.31b): 9.86 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (323.0m) vs 12m ago -0.31% < -2% |
| Gross Margin: 9.66% > 18% (prev 11.71%; Δ -2.05% > 0.5%) |
| Asset Turnover: 85.83% > 50% (prev 97.92%; Δ -12.09% > 0%) |
| Interest Coverage Ratio: -0.18 > 6 (EBIT TTM -96.0m / Interest Expense TTM 530.0m) |
| A: 0.11 (Total Current Assets 11.1b - Total Current Liabilities 7.19b) / Total Assets 34.0b |
| B: 0.20 (Retained Earnings 6.71b / Total Assets 34.0b) |
| C: -0.00 (EBIT TTM -96.0m / Avg Total Assets 34.6b) |
| D: 0.42 (Book Value of Equity 10.0b / Total Liabilities 23.8b) |
| Altman-Z'' = 1.82 = BBB |
| DSRI: 1.00 (Receivables 3.26b/3.79b, Revenue 29.7b/34.5b) |
| GMI: 1.21 (GM 11.71% / 9.66%) |
| AQI: 0.85 (AQ_t 0.17 / AQ_t-1 0.20) |
| SGI: 0.86 (Revenue 29.7b / 34.5b) |
| TATA: -0.10 (NI -793.0m - CFO 2.57b) / TA 34.0b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of June 27, 2026, the stock is trading at USD 55.73 with a total of 4,120,505 shares traded. Over the past week, the price has changed by -7.22%, over one month by -18.40%, over three months by -27.54% and over the past year by +2.80%.
Current recommended Stop Loss: 51.80 (which is 7.1% or 1.6 ATR below the current price).
LyondellBasell Industries has received a consensus analysts rating of 3.27. Therefore, it is recommended to hold LYB.
- StrongBuy: 5
- Buy: 1
- Hold: 13
- Sell: 1
- StrongSell: 2
| Analysts Target Price | 80.4 | 44.2% |
P/E Forward = 7.5358
P/S = 0.6534
P/B = 1.9312
P/EG = 1.5257
Revenue TTM = 29.7b USD
EBIT TTM = -96.0m USD
EBITDA TTM = 1.31b USD
Long Term Debt = 11.2b USD (from longTermDebt, last quarter)
Short Term Debt = 1.69b USD (from shortTermDebt, last quarter)
Debt = 15.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.33b
Net Debt = 12.9b USD (calculated: Debt 15.6b - CCE 2.64b)
Enterprise Value = 32.3b USD (19.4b + Debt 15.6b - CCE 2.64b)
Interest Coverage Ratio = -0.18 (Ebit TTM -96.0m / Interest Expense TTM 530.0m)
EV/FCF = 11.61x (Enterprise Value 32.3b / FCF TTM 2.79b)
FCF Yield = 8.62% (FCF TTM 2.79b / Enterprise Value 32.3b)
FCF Margin = 9.39% (FCF TTM 2.79b / Revenue TTM 29.7b)
Net Margin = -2.67% (Net Income TTM -793.0m / Revenue TTM 29.7b)
Gross Margin = 9.66% ((Revenue TTM 29.7b - Cost of Revenue TTM 26.8b) / Revenue TTM)
Gross Margin QoQ = 9.74% (prev 6.49%)
Tobins Q-Ratio = 0.95 (Enterprise Value 32.3b / Total Assets 34.0b)
Interest Expense / Debt = 3.40% (Interest Expense 530.0m / Debt 15.6b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -75.8m (EBIT -96.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.54 (Total Current Assets 11.1b / Total Current Liabilities 7.19b)
Debt / Equity = 1.55 (Debt 15.6b / totalStockholderEquity, last quarter 10.0b)
Debt / EBITDA = 9.86 (Net Debt 12.9b / EBITDA 1.31b)
Debt / FCF = 4.65 (Net Debt 12.9b / FCF TTM 2.79b)
Total Stockholder Equity = 10.7b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.29% (Net Income -793.0m / Total Assets 34.0b)
RoE = -7.44% (Net Income TTM -793.0m / Total Stockholder Equity 10.7b)
RoCE = -0.44% (EBIT -96.0m / Capital Employed (Equity 10.7b + L.T.Debt 11.2b))
RoIC = -0.28% (negative operating profit) (NOPAT -75.8m / Invested Capital 27.0b)
WACC = 5.68% (E(19.4b)/V(35.0b) * Re(8.08%) + D(15.6b)/V(35.0b) * Rd(3.40%) * (1-Tc(0.21)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.13 | Cagr: -0.41%
[DCF] Terminal Value 77.97% ; FCFF base≈2.28b ; Y1≈2.61b ; Y5≈3.84b
[DCF] Fair Price = 139.0 (EV 57.8b - Net Debt 12.9b = Equity 44.9b / Shares 322.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.18 | # QB: 0
Revenue Correlation: -99.25 | Revenue CAGR: -12.59% | SUE: -0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.23 | Chg30d=+0.16% | Revisions=-14% | Analysts=14
EPS next Quarter (2026-09-30): EPS=3.65 | Chg30d=-0.56% | Revisions=-43% | Analysts=14
EPS current Year (2026-12-31): EPS=9.47 | Chg30d=-3.09% | Revisions=-14% | GrowthEPS=+457.3% | GrowthRev=+15.0%
EPS next Year (2027-12-31): EPS=7.53 | Chg30d=+1.85% | Revisions=+0% | GrowthEPS=-20.5% | GrowthRev=-5.0%
[Analyst] Revisions Ratio: -43%